A Study to Assess the Safety and Efficacy of LB1410 in Participants With Advanced Solid Tumor or Lymphoma（Keyplus-001）

This is a Phase I study designed to evaluate if experimental anti-PD-1 and anti-TIM-3 bispecific antibody, LB1410, is safe, tolerable and efficacious in participants with advanced solid tumors or lymphoma.

Trial Details

NCT ID
NCT05357651
Phase
PHASE1
Sponsor
L & L Bio Co., Ltd., Ningbo, China
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • LB1410
Locations (sample)
  • Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

  • Must be ≥ 18 years of age
  • For dose escalation and safety expansion phases only, patient must have histologically or cytologically confirmed advanced and/or metastatic solid …
  • Cohort specific inclusion criteria:
  • Cohort A: NSCLC patients with histologically confirmed advanced or metastatic NSCLC who have previously failed anti-PD1/anti-PD-L1 antibody and pla…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →